share_log

Puma Biotechnology Announces Exclusive License Agreement With Takeda For The Development And Commercialization of Alisertib; Takeda Will Receive An Upfront License Fee Of $7M And Is Eligible To Receive Potential Future Milestone Payments Of Up To $287.3M

Benzinga Real-time News ·  Sep 20, 2022 16:08
Puma Biotechnology Announces Exclusive License Agreement With Takeda For The Development And Commercialization of Alisertib; Takeda Will Receive An Upfront License Fee Of $7M And Is Eligible To Receive Potential Future Milestone Payments Of Up To $287.3M
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment